Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab

OBJECTIVE: The goal is to evaluate avelumab, an anti-PD-L1 monoclonal immunoglobulin G antibody labeled with zirconium-89 in human PD-L1-expressing cancer cells and mouse xenografts for clinical translation. METHODS: [(89)Zr]Zr-DFO-PD-L1 monoclonal antibody (mAb) was synthesized using avelumab conju...

Descripción completa

Detalles Bibliográficos
Autores principales: Jagoda, Elaine M., Vasalatiy, Olga, Basuli, Falguni, Opina, Ana Christina L., Williams, Mark R., Wong, Karen, Lane, Kelly C., Adler, Steve, Ton, Anita Thein, Szajek, Lawrence P., Xu, Biying, Butcher, Donna, Edmondson, Elijah F., Swenson, Rolf E., Greiner, John, Gulley, James, Eary, Janet, Choyke, Peter L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498777/
https://www.ncbi.nlm.nih.gov/pubmed/31044647
http://dx.doi.org/10.1177/1536012119829986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498777/
https://www.ncbi.nlm.nih.gov/pubmed/31044647
http://dx.doi.org/10.1177/1536012119829986

Ejemplares similares